Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

ctive DNA damage, irreversible G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Ovarian Cancer

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2008 there will be an estimated 21,650 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. Following frontline treatment, recurrence rates among ovarian cancer patients are high. Treatment options remain limited following relapse and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 This report is a ... industry. For an overview analysis, the report introduces ... chain structure, industry overview, policy analysis, and news ... has witnessed rapid development with key manufacturers ... This report mentions quartz tubing upstream raw materials ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 ... today that it has entered into a technology ... Company (ADM) to apply DNA2.0’s proprietary protein engineering ... engineering process. , “We are extremely excited that ... engineering platform. This proprietary bioengineering technology has ...
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic disease, today announced the next step in ... premier bio-analytics solutions provider with the naming of current ... and Chief Executive Officer, while current Chairman of the ... to serve as Chairman. These changes are effective January ...
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... FT. LAUDERDALE, Fla., July 30 OmniComm Systems, Inc. ... capture (EDC) solutions for clinical trials announced today that a ... provide eClinical solutions in connection with two of the CRO,s ... 700 subjects. Additional details were not disclosed. Phase IV studies ...
... , RALEIGH, N.C. , July 30 SmartGene, ... of genetic data, today announced that it has entered into an ... technology and integrated Web-based services to support more rapid and precise ... , Some bacteria and fungi do not grow quickly ...
... 30 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology ... based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), ... with its vaccine candidate for the Influenza A (H1N1) ... a single dose of 5 micrograms induced a positive ...
Cached Biology Technology:Growing Midwestern Clinical Research Organization Selects OmniComm Systems to Provide eClinical Solutions for Phase IV Studies 2SmartGene's Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 3
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... of the "iPhone 5S Fingerprint Sensor - ... report to their offering. ... of AuthenTec in July 2012, Apple introduced the ... is currently the only device of Apple incorporating ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... -- Look out, Indiana Jones. Dan Shain ... to frozen glaciers and the steamy Amazon planned, all ... cinematic icon, Shain, an associate professor of biology at ... returns home with treasure. He,s mined for ice ...
... Western Reserve University have developed a technique that has ... within hours, as opposed to the two days it ... mice, drug delivery time from injection to the cancer ... Using this as a model for potential human use, ...
... is a significant challenge for researchers. That challenge is prompting ... that data and to make it readily available. The ... Disease has created a new collaboration tool, WikiPathways to focus ... "Biological pathways connect genes and proteins in systems that ...
Cached Biology News:Rutgers biologist to study worms in Amazon, glaciers 2Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 2Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 3Gladstone scientists create Wikipathways to foster research collaboration 2
... This antibody is generated from rabbits immunized ... within aa 50~150 of human PLAU. Purified ... 0.09% (W/V) sodium azide. This antibody is ... eluted out with both high and low ...
... is a compact, lightweight, high current power supply ... 2500 milliamps. It is an excellent choice for ... It is also ideal for all types of ... set to automatically end a run and wil ...
... For use in Refrigerated Vapor Trap ... Vacuum Source (UVS) Models UVS400, UVS400A and ... polymer suitable for use for temperatures ranging ... has excellent thermal stability and does not ...
... proteomics demands the detection of very small ... the AXIMA-CFRplus with improved resolution (20,000) and ... increased confidence in protein identification. The AXIMA-CFRplus ... automated sample target handling and the ability ...
Biology Products: